使用重组因子VIII Fc或重组因子IX Fc对年龄≥50岁的成人血友病A或B患者进行预防治疗的长期临床结果。 - Suppr

Suppr

超能文献

Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B.

作者信息

Quon Doris, Jackson Shannon, Alvarez-Román María Teresa, Khan Umer, Casiano Sandra, Ragni Margaret V, Rangarajan Savita

机构信息

Orthopaedic Hemophilia Treatment Center, Luskin Orthopaedic Institute for Children, Los Angeles, CA.

Providence Health Care, St. Paul's Hospital, Vancouver, BC, Canada.

出版信息

Blood Adv. 2024 Sep 24;8(18):4751-4755. doi: 10.1182/bloodadvances.2023012462.

DOI:10.1182/bloodadvances.2023012462

PMID:39042888

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11414653/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dddb/11414653/b861c15f9734/BLOODA_ADV-2023-012462-ga1.jpg

相似文献

Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B.使用重组因子VIII Fc或重组因子IX Fc对年龄≥50岁的成人血友病A或B患者进行预防治疗的长期临床结果。

Blood Adv. 2024 Sep 24;8(18):4751-4755. doi: 10.1182/bloodadvances.2023012462.

Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.瑞典使用重组因子VIIIFc与重组因子VIII进行终生预防治疗重度甲型血友病的成本效用分析。

J Med Econ. 2018 Apr;21(4):318-325. doi: 10.1080/13696998.2017.1405816. Epub 2017 Dec 4.

rFVIIIFC for hemophilia A prophylaxis.rFVIIIFC 用于血友病 A 预防。

Expert Rev Hematol. 2018 Dec;11(12):937-943. doi: 10.1080/17474086.2018.1549478. Epub 2018 Dec 3.

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.血友病 A 患者中重组因子 VIII Fc 融合蛋白的安全性和长效活性。

Blood. 2012 Mar 29;119(13):3031-7. doi: 10.1182/blood-2011-09-382846. Epub 2012 Jan 5.

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.用于治疗重型血友病 A 的重组凝血因子 VIII Fc 融合蛋白：ASPIRE 扩展研究的最终结果。

Haemophilia. 2020 May;26(3):494-502. doi: 10.1111/hae.13953. Epub 2020 Mar 30.

[Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].[转向使用重组因子VIII Fc融合蛋白的研究：30例重度A型血友病患者的情况]

Ann Biol Clin (Paris). 2020 Feb 1;78(1):35-46. doi: 10.1684/abc.2020.1520.

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.Fc 融合技术在重组凝血因子 VIII 替代治疗中的新获益。

Haemophilia. 2020 Nov;26(6):958-965. doi: 10.1111/hae.14123. Epub 2020 Sep 3.

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.用于诱导有抑制剂的重度 A 型血友病患者免疫耐受的重组凝血因子 VIII Fc 融合蛋白：一项回顾性分析。

Haemophilia. 2018 Mar;24(2):245-252. doi: 10.1111/hae.13413. Epub 2018 Feb 13.

Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.预测使用长效预防因子 VIII 治疗严重甲型血友病患者的结果：假设性决策分析。

J Thromb Haemost. 2016 Nov;14(11):2141-2147. doi: 10.1111/jth.13440. Epub 2016 Oct 3.

Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.A型或 B 型血友病患者接受延长半衰期重组凝血因子 VIII 和 IX Fc 融合蛋白治疗的手术结局：北欧国家的真实世界经验。

Haemophilia. 2022 Sep;28(5):713-719. doi: 10.1111/hae.14585. Epub 2022 May 16.

本文引用的文献

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: analysis from the PROTECT VIII study.达莫妥珠单抗α聚乙二醇预防治疗对年龄≥40岁的重度甲型血友病合并症患者的疗效与安全性：来自PROTECT VIII研究的分析

Ther Adv Hematol. 2023 Apr 22;14:20406207231166779. doi: 10.1177/20406207231166779. eCollection 2023.

Cardiovascular Risk Factors in Patients with Congenital Hemophilia: A Focus on Hypertension.先天性血友病患者的心血管危险因素：聚焦高血压

Diagnostics (Basel). 2022 Nov 24;12(12):2937. doi: 10.3390/diagnostics12122937.

Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia-Hematology Utilization Group Study Part VII (HUGS VII).血友病老年患者的合并症、健康相关生活质量及医疗保健利用情况——血液学利用组研究第七部分（HUGS VII）

J Blood Med. 2022 May 9;13:229-241. doi: 10.2147/JBM.S354526. eCollection 2022.

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results.在既往未经治疗的甲型血友病患者中对延长半衰期重组凝血因子VIII融合蛋白（rFVIIIFc）的首次研究：PUPs A-LONG最终结果。

Blood. 2022 Jun 30;139(26):3699-3707. doi: 10.1182/blood.2021013563.

Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.PUPs B-LONG 研究的最终结果：评估 rFIXFc 在既往未治疗的乙型血友病患者中的安全性和疗效。

Blood Adv. 2021 Jul 13;5(13):2732-2739. doi: 10.1182/bloodadvances.2020004085.

WFH Guidelines for the Management of Hemophilia, 3rd edition.《血友病管理的居家指南》第三版

Haemophilia. 2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3.

Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.长达 5 年的重组凝血因子 IX Fc 融合蛋白治疗乙型血友病患者的长期安全性和持续疗效：B-YOND 扩展研究结果。

Haemophilia. 2020 Nov;26(6):e262-e271. doi: 10.1111/hae.14036. Epub 2020 Jun 4.

Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.儿童重度 A 型血友病预防治疗的青年期结局：联合结局持续研究结果。

Blood Adv. 2020 Jun 9;4(11):2451-2459. doi: 10.1182/bloodadvances.2019001311.

Haemophilia. 2020 May;26(3):494-502. doi: 10.1111/hae.13953. Epub 2020 Mar 30.

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.预防性使用重组凝血因子 VIII Fc 融合蛋白治疗重型 A 型血友病患者的关节健康改善。

Haemophilia. 2018 Jan;24(1):77-84. doi: 10.1111/hae.13353. Epub 2017 Oct 30.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验